RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor
Aberrant activation of the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal–regulated kinase pathway is a frequent cause of cancer. Allosteric MEK inhibitors block this pathway by binding RAF-MEK complexes to prevent activation ...